PT1819830E - Métodos para engenharia de anticorpos - Google Patents

Métodos para engenharia de anticorpos Download PDF

Info

Publication number
PT1819830E
PT1819830E PT05851359T PT05851359T PT1819830E PT 1819830 E PT1819830 E PT 1819830E PT 05851359 T PT05851359 T PT 05851359T PT 05851359 T PT05851359 T PT 05851359T PT 1819830 E PT1819830 E PT 1819830E
Authority
PT
Portugal
Prior art keywords
antibody
amino acid
methods
acid sequence
substitutable position
Prior art date
Application number
PT05851359T
Other languages
English (en)
Inventor
Guo-Liang Yu
Fernando Jose Rebelo Do Couto
Stacey Ellen Wallace
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Publication of PT1819830E publication Critical patent/PT1819830E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
PT05851359T 2004-11-08 2005-11-02 Métodos para engenharia de anticorpos PT1819830E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/984,473 US7462697B2 (en) 2004-11-08 2004-11-08 Methods for antibody engineering

Publications (1)

Publication Number Publication Date
PT1819830E true PT1819830E (pt) 2011-07-20

Family

ID=36316567

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05851359T PT1819830E (pt) 2004-11-08 2005-11-02 Métodos para engenharia de anticorpos

Country Status (12)

Country Link
US (5) US7462697B2 (pt)
EP (1) EP1819830B1 (pt)
JP (2) JP2008518619A (pt)
CN (2) CN101080496A (pt)
AT (1) ATE507302T1 (pt)
CA (2) CA2585742C (pt)
DE (1) DE602005027737D1 (pt)
DK (1) DK1819830T3 (pt)
ES (1) ES2362792T3 (pt)
HK (1) HK1200854A1 (pt)
PT (1) PT1819830E (pt)
WO (1) WO2006050491A2 (pt)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP4342995A2 (en) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
CA2652392C (en) * 2006-05-19 2017-10-10 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
PT3187506T (pt) * 2007-05-21 2019-04-24 Alderbio Holdings Llc Anticorpos contra il-6 e sua utilização
AU2013204593B2 (en) * 2007-05-21 2016-01-21 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CA2689941C (en) * 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
US9908945B2 (en) * 2007-06-25 2018-03-06 Esbatech, An Alcon Biomedical Research Unit Llc Sequence based engineering and optimization of single chain antibodies
CA2695484C (en) * 2007-08-20 2018-05-01 Glaxo Group Limited Production method of therapeutic proteins based on codon adaptation
MX2010003450A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
RU2567100C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US8496937B2 (en) 2009-03-30 2013-07-30 Edimer Pharmaceuticals, Inc. Preparation of isolated agonist anti-EDAR monoclonal antibodies
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2954779B1 (en) 2009-12-10 2019-02-06 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
CA2782578C (en) * 2009-12-22 2019-03-05 F. Hoffmann-La Roche Ag Sequence dependent aggregation
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
RU2013115927A (ru) * 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
EP2681243B1 (en) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
JP6258194B2 (ja) * 2011-05-06 2018-01-10 ネックスヴェット オーストラリア プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
US9580496B2 (en) * 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
DK2739649T3 (en) 2011-08-05 2018-01-08 Bioasis Technologies Inc P97 FRAGMENTS WITH TRANSFER ACTIVITY
US9988687B2 (en) 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6117225B2 (ja) 2011-11-02 2017-04-19 アペクシジェン， インコーポレイテッド 抗ｋｄｒ抗体およびその使用方法
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN110066335B (zh) 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法
US9944719B2 (en) 2012-12-05 2018-04-17 Hoffman-La Roche Inc. Dual targeting
CN103145834B (zh) * 2013-01-17 2015-03-18 广州泰诺迪生物科技有限公司 一种抗体人源化改造方法
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
JP6525432B2 (ja) 2013-03-14 2019-06-05 アペクシジェン， インコーポレイテッド 抗ｒａｎｋｌ抗体および使用方法
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015026606A1 (en) 2013-08-19 2015-02-26 Epitomics, Inc. Antibody identification by lineage analysis
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
DK3071595T3 (da) 2013-11-19 2019-07-01 Fredax Ab Humaniseret anti-kallikrein-2-antistof
US10732186B2 (en) 2013-12-03 2020-08-04 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
CA2936805C (en) 2014-01-17 2024-02-20 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
CN106413757B (zh) 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 p97-多核苷酸结合物
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101618458B1 (ko) 2014-11-28 2016-05-10 강원대학교산학협력단 항체에서 항원-항체 결합력과 양의 상관관계를 갖는 아미노산 서열에 대한 정보를 얻는 방법
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6886922B2 (ja) 2015-02-13 2021-06-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｌ型電位開口型チャネルに対する抗体および関連方法
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
AU2017285995B2 (en) * 2016-06-14 2023-11-30 Agency For Science, Technology And Research PRL3 antibody
US20190352426A1 (en) 2016-08-03 2019-11-21 Achaogen, Inc. Plazomicin antibodies and methods of use
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3740509A4 (en) 2018-01-17 2022-06-22 Apexigen, Inc. ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
JP2021525779A (ja) 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ， インク． 機能性および製造可能性を改善するための普遍的なまたは正規化された抗体フレームワーク
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
CN112533956A (zh) * 2018-07-31 2021-03-19 海德堡医药研究有限责任公司 针对psma的人源化抗体
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6093853A (en) 1997-07-04 2000-07-25 Nok Corporation Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent
US6342587B1 (en) 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7115716B2 (en) 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP1505075B1 (en) * 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
AU2003264009A1 (en) * 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
PT1748074E (pt) * 2003-01-17 2012-01-16 Danisco Método para a produção in situ de um emulsificador num alimento
ES2347959T3 (es) * 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
US20070026398A1 (en) * 2003-03-03 2007-02-01 Farnsworth Amanda L Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering

Also Published As

Publication number Publication date
CA2585742C (en) 2016-04-12
HK1200854A1 (en) 2015-08-14
ES2362792T3 (es) 2011-07-13
CA2901238A1 (en) 2006-05-11
WO2006050491A2 (en) 2006-05-11
JP2012095654A (ja) 2012-05-24
DK1819830T3 (da) 2011-07-04
US8404816B2 (en) 2013-03-26
US20060099204A1 (en) 2006-05-11
CN101080496A (zh) 2007-11-28
JP2008518619A (ja) 2008-06-05
ATE507302T1 (de) 2011-05-15
EP1819830A2 (en) 2007-08-22
US10613094B2 (en) 2020-04-07
CA2901238C (en) 2020-03-24
US20120329069A1 (en) 2012-12-27
WO2006050491A3 (en) 2006-12-28
DE602005027737D1 (de) 2011-06-09
US7960517B2 (en) 2011-06-14
JP5096611B2 (ja) 2012-12-12
US7462697B2 (en) 2008-12-09
US20120003671A1 (en) 2012-01-05
CN103980362A (zh) 2014-08-13
US20090155824A1 (en) 2009-06-18
EP1819830A4 (en) 2009-03-11
CA2585742A1 (en) 2006-05-11
US20150038370A1 (en) 2015-02-05
EP1819830B1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
HK1200854A1 (en) Methods for antibody engineering
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
MX2020001873A (es) Agentes de union.
WO2008036688A3 (en) Optimized antibodies that target hm1.24
NL300919I2 (nl) Brodalumab
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
IL177337A0 (en) Less immunogenic binding molecules
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
EP3202786A3 (en) Sequence based engineering and optimization of single chain antibodies
SI1697421T1 (sl) Bispecifična protitelesa
IL184103A (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
WO2008065384A3 (en) Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
WO2013087857A3 (de) Antikörper gegen toxine von c. difficile
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
WO2008140580A3 (en) Specific antibody selection by selective elution conditions
NZ629387A (en) Monoclonal antibodies against amyloid beta protein and uses thereof
WO2003091700A3 (en) Epitope mapping using nuclear magnetic resonance
WO2008155291A3 (en) Chlamydia antigens
TH87431B (th) แอนติบอดีชนิดแอนติ-il-12, เอพิโทป, สารผสม, วิธี และการใช้